Thread by @StephenVLiu

#WCLC20 Results from randomized phase II of nivo vs nivo/ipi in #EGFR mutant NSCLC. Unfortunately, study stopped for futility (n=31) but glad to see results presented. #LCSM @IASLC

#WCLC20 Only 1 response (RR 3%) and median PFS of 1.3 months. Spider plot shows some with modest duration stable disease (but others with rapid progression - suggestive of TKI flare?) #LCSM

#WCLC20 Treatment was well tolerated - we are concerned about safety when TKI follows immunotherapy, not really the other way around (as done here). #LCSM

#WCLC20 Promising biomarker work with those getting more benefit showing "hot" tumors and fewer myeloid derived suppressor cells. But analyses limited by the small number of patients who derived benefit (and only 1 who had a response). #LCSM

#WCLC20 Noted that some who had an extracranial response had intracranial progression. Echoes my experience - when osimertinib used to control CNS disease, withdrawal often leads to loss of CNS control. Lesson: PD1/CTLA4 alone not effective in #EGFR NSCLC. Need to learn why #LCSM